Search

Search Constraints

You searched for: Author/Creator Loftus, E V

Search Results

1. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021)

2. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021)

6. DOP004 Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY. (16th January 2018)

7. DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease. (16th January 2018)

8. DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. (16th January 2018)

9. DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's disease but not ulcerative colitis: a multi-centre consortium analysis. (16th January 2018)

10. DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis. (16th January 2018)